EXACT Sciences Corp. (EXAS)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about EXACT Sciences Corp. (EXAS)
Company Performance

Current Price

as of Oct 16, 2024

$70.62

P/E Ratio

N/A

Market Cap

$13.05B

Description

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Metrics

Overview

  • HQMadison, WI
  • SectorHealth Technology
  • IndustryMedical Specialties
  • TickerEXAS
  • Price$70.62+0.96%

Trading Information

  • Market Cap$13.05B
  • Float98.49%
  • Average Daily Volume (1m)1,865,567
  • Average Daily Volume (3m)2,469,681
  • EPS-$0.96

Company

  • Revenue$2.61B
  • Rev Growth (1yr)12.41%
  • Net Income-$15.81M
  • Gross Margin69.52%
  • EBITDA Margin4.45%
  • EBITDA$31.09M
  • EV$9.62B
  • EV/Revenue3.68
  • P/EN/A
  • P/S4.98
  • P/B4.09
Documents
SEC Filings
8-K (2024-07-31)
8-K (2024-06-17)
8-K (2024-06-03)
8-K (2024-05-08)
8-K (2024-04-25)
8-K (2024-04-17)
8-K (2024-04-15)
8-K (2024-02-21)
8-K (2024-01-08)
8-K (2023-11-01)
8-K (2023-08-01)
8-K (2023-06-21)
8-K (2023-06-12)
8-K (2023-05-09)
8-K (2023-03-17)
8-K (2023-03-03)
8-K (2023-03-01)
8-K (2023-02-21)
8-K (2023-01-09)
10-Q (2024-07-31)
10-Q (2024-05-08)
10-Q (2023-11-01)
10-Q (2023-08-01)
10-Q (2023-05-09)
10-K (2024-02-21)
10-K (2023-02-21)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report (2023-11-01)
Earnings Report (2023-08-01)
Factset Street Account
StreetAccount Metrics Recap - EXACT Sciences Q3 Earnings ($63.47, 0.00) (2023-11-01T20:16:10Z)
StreetAccount Earnings Call Q&A Summary: EXACT Sciences Q3 ($ 63.52, 0.00) (2023-11-01T22:47:50Z)
StreetAccount Consensus Metrics Preview - EXACT Sciences Q3 Earnings ($62.02, +0.64) (2023-10-27T13:56:58Z)
EXACT Sciences trading higher, we are looking for news ($69.71, +5.11) (2023-12-19T19:39:16Z)
EXACT Sciences reports Q3 EPS $0.00 ($63.73, 0.00) (2023-11-01T20:12:35Z)
Exact Sciences files patent infringement lawsuit against Geneoscopy ($61.17, 0.00) (2023-11-17T12:11:47Z)
Exact Sciences announces that next-generation Cologuard test demonstrates high sensitivity and specificity in pivotal BLUE-C study, significantly outperforming FIT for cancer and precancer detection ($64.25, 0.00) (2023-10-22T19:23:34Z)
Wikipedia
Exact_Sciences_(company)
Factset
Factset Business Description